ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx

Isis Pharmaceuticals, Inc.

announced today that it has earned a $5 million milestone payment from GSK related to the initiation of a Phase 1 study of ISIS-GSK4-LRx (formerly ISIS-GSK4Rx) in healthy volunteers. ISIS-GSK4-LRx is one of five drugs in development with GSK and is designed to treat patients with an undisclosed ocular disorder.